Veraxa Biotech AG
VRXA
8 hedge funds and large institutions have $600K invested in Veraxa Biotech AG in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.34% more ownership
Funds ownership: 0% → 0.34% (+0.34%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$1.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.26M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$957K |
| 4 |
HF
HRT Financial
New York
|
+$151K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$86.6K |
Top Sellers
VRXA Hedge Fund Activity: Q2 2026 in Review
8 of the 8,336 institutional investors tracked by Wall St. Rank reported a position in Veraxa Biotech AG (VRXA) for Q2 2026, worth a combined $600K.
Buyers outnumbered sellers: 8 funds opened new VRXA positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Picton Mahoney Asset Management, opening a new position worth an estimated $1.4M.
- 8 institutional investors held Veraxa Biotech AG (VRXA) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $600K of Veraxa Biotech AG stock for Q2 2026.
- 8 funds opened new Veraxa Biotech AG positions in Q2 2026 and 0 closed out, a net change of +8 holders.
- The largest Veraxa Biotech AG buyer in Q2 2026 was Picton Mahoney Asset Management, an estimated $1.4M added.
Based on aggregated 13F filings for Q2 2026.